According to Fortune Business Insights, the global Continuous Renal Replacement Therapy (CRRT) market was valued at USD 1.16 billion in 2024. The market is projected to grow from USD 1.25 billion in 2025 to USD 2.14 billion by 2032, exhibiting a CAGR of 8.0% during the forecast period. In 2024, North America dominated the CRRT market with a market share of 39.66%.
Leading Players in the CRRT Market
- Baxter (U.S.)
- B Braun SE (Germany)
- Fresenius Medical Care AG & Co. KGaA (Germany)
- Asahi Kasei Medical Co., Ltd. (Japan)
- NIPRO (Japan)
- TORAY MEDICAL CO., LTD. (Japan)
- Nikkiso Co., Ltd. (Japan)
- Medtronic (Ireland)
Key Industry Development
In December 2023, Cheshire Medical Center, part of Dartmouth Health, began offering CRRT to ICU patients suffering from kidney failure—reinforcing the essential role of CRRT in intensive care .
Market Drivers & Restraints
Market Drivers
- High AKI Incidence & ICU Admissions: Acute Kidney Injury is on the rise, especially among critically ill and sepsis patients. ICU admissions also surged during the COVID‑19 pandemic, with AKI a key complication .
- Technological Innovations: Systems like Baxter’s PrisMax 2 launch in 2021 and advances in fluid management, automation, and AI-enabled remote monitoring enhance CRRT effectiveness .
Market Restraints
- High Cost of CRRT: CRRT is significantly more expensive than intermittent dialysis—a U.S. survey estimates daily costs of ~USD 870 vs. USD 270, impacting adoption in cost-sensitive settings .
- Operational Complexity & Expertise Needs: CRRT setup requires skilled personnel and strict protocols. Plus, pediatric CRRT systems now face additional regulatory scrutiny (e.g., FDA’s Class II classification in Sept 2024) .
Market Report Coverage
The Fortune Business Insights report covers:
- Market forecasts up to 2032
- Segmentation by product (systems, consumables), modality (SCUF, CVVH, CVVHD, CVVHDF)
- Regional analysis: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
- Market dynamics, competitive landscape, recent product launches
Competitive Landscape
The market is moderately consolidated. Key strength areas include:
- Baxter: With its AK 98 CRRT machine and PrisMax 2 platform, Baxter leads in advanced fluid and automation systems .
- Fresenius Medical Care: Offers the PRISMAFLEX system and a global dialysis network, including Covid-era innovations like the multiBic dialysate .
- B Braun SE: Expanded offerings through acquisitions (e.g., Intermedt Medizin & Technik in 2022) and has a strong consumables lineup .
- Emerging Competitors: NIPRO, Asahi Kasei, Medtronic, Toray, and Nikkiso are increasingly entering the market via product development, partnerships, or localized distribution .
Market Segmentation
By Product Type
The consumables segment led in 2024, including filters, dialysates, replacement fluids, catheters, and tubing—selected due to frequency of use, lower individual costs, and pandemic-driven demand .
By Modality
The CVVHDF (Continuous Venovenous Hemodiafiltration) modality accounted for the largest share in 2024, appreciated for its combined convective and diffusive solute removal .
Other modalities include:
- SCUF (Slow Continuous Ultrafiltration)
- CVVH (Continuous Venovenous Hemofiltration)
- CVVHD (Continuous Venovenous Hemodialysis)
Regional Insights
North America
Dominating with ~39.6% share and revenues of USD 0.46 billion in 2024—driven by high AKI rates, advanced ICU infrastructure, and innovation (e.g., Medtronic's Carpediem pediatric CRRT launched in 2020) .
Europe
Second largest region—spurred by rising kidney disease prevalence (e.g., 3.5 million CKD cases in the UK) and supportive healthcare policies .
Asia Pacific
Fastest growing region. Japan has notably high AKI rates (~40% ICU incidence), pushing demand for CRRT .
Explore the full research report with detailed insights and TOC:https://www.fortunebusinessinsights.com/continuous-renal-replacement-therapy-crrt-market-102547
Future Market Scope
- Continued growth at ~8% CAGR through 2032, driven by AKI prevalence, ICU capacity expansion, and rising adoption of CRRT
- Innovations: Compact/home-use devices, enhanced automation, biocompatible membranes, AI-driven analytics
- Pediatric CRRT is an emerging area—FDA now classifies pediatric systems as Class II devices, opening up R&D opportunities .
- Cost-mitigation strategies—such as modular systems, consumable reuse protocols, and tele-ICU integration—may boost adoption in resource-limited settings.
Conclusion
The CRRT market is poised for robust expansion between 2025–2032, driven by medical necessity and technological innovation. As key players enhance their offerings and geographical coverage, and emerging markets adopt CRRT more widely, opportunities are vast. Addressing cost, operational complexity, and training gaps will be essential to achieving broader global adoption. With support from innovation, regulation, and healthcare infrastructure, CRRT’s role in acute kidney injury management is set to deepen, improving patient outcomes and driving market growth.
About Us:
Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in.
Our reports are a blend of quantitative and qualitative analysis, aimed at helping businesses achieve sustainable growth. Our experienced analysts and consultants use leading research methodologies to provide comprehensive market assessments enriched with relevant data.
At Fortune Business Insights, we aim to highlight growth opportunities for our clients, offering insights and recommendations that help them navigate technological and market changes. Our consulting services are designed to help companies uncover hidden opportunities and address competitive challenges.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free),
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com
この記事をシェア
